Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Double-Blind, Placebo-Controlled, Randomized Trial of Selenium in Graves Hyperthyroidism
source: The Journal of Clinical Endocrinology and Metabolism
authors: Kahaly GJ, Riedl M, König J, Diana T, Schomburg Lsummary/abstract:
Supplemental selenium (Se) may affect the clinical course of Graves disease (GD).
Evaluate efficacy of add-on Se on medical treatment in GD.
Double-blind, placebo-controlled, randomized supplementation trial.
Academic endocrine outpatient clinic.
Seventy untreated hyperthyroid patients with GD.
Additionally to methimazole (MMI), patients received for 24 weeks either sodium selenite 300 µg/d po or placebo. MMI was discontinued at 24 weeks in euthyroid patients.
Main Outcome Measures:
Response rate (week 24), recurrence rate (week 36), and safety.
A response was registered in 25 of 31 patients (80%) and in 27 of 33 (82%) at week 24 [odds ratio (OR) 0.93; 95% confidence interval (CI), 0.26 to 3.25; P = 0.904] in the Se (+MMI) and placebo (+MMI) groups, respectively. During a 12-week follow-up, 11 of 23 (48%) and 12 of 27 (44%) relapsed (OR 1.13; 95% CI, 0.29 to 2.66; P = 0.81) in the Se and placebo groups, respectively. Serum concentrations of Se and selenoprotein P were unrelated to response or recurrence rates. At week 36, 12 of 29 (41%) and 15 of 33 (45%) were responders and still in remission in the Se and placebo groups, respectively (OR 0.85; 95% CI, 0.31 to 2.32; P = 0.80). Serum levels of free triiodothyronine/free tetraiodothyronine, thyroid-stimulating hormone receptor antibody, prevalence of moderate to severe Graves orbitopathy, thyroid volume, and MMI starting dose were significantly lower in responders than in nonresponders. A total of 56 and 63 adverse events occurred in the Se and placebo groups, respectively (P = 0.164), whereas only one drug-related side effect (2.9%) was noted in 35 patients on placebo + MMI.
Supplemental Se did not affect response or recurrence rates in GD.
read more full text
For Parents: Hyperthyroidism and Graves’ DiseaseWhat is the Thyroid? The thyroid is a s...
Current Diagnosis and Management of Graves’ Disease.Graves' disease is an autoimmune disorde...
A Survey of the Young Person’s Experience of Graves’ Disease and Its ManagementObjective: A suboptimal quality of li...
Which Factors are Associated With Quality of Life in Patients With Graves’ Orbitopathy Presenting for Orbital ...Purpose: Graves' orbitopathy (GO) is as...
Thyroidectomy for Graves’The surgical treatment of Graves’ dise...
Denise Sujin Kim, MDDenise S. Kim, MD, is an Assistant Profe...
Thyroid Eye Disease: The Battle of the Bulge, Part Ihttps://www.youtube.com/watch?v=L3fReHgz...
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.